Now, IL-21 has been used in phase I and II trials in cancer and early results demonstrated that recombinant IL-21 administration has an acceptable safety profile and has demonstrated encouraging activity in early phase renal cell carcinoma and melanoma trials (218). This evidence concerns the gene IL21 and hereditary clear cell renal cell carcinoma.